Characterization of patients with infliximab-induced lupus erythematosus and outcomes after retreatment with a second anti-TNF agent

Inflammatory Bowel Diseases
Sreedhar SubramanianJ R Korzenik

Abstract

Drug-induced lupus erythematosus (DILE) due to infliximab therapy for inflammatory bowel disease (IBD) is an uncommon occurrence. It remains uncertain whether patients with infliximab-induced DILE could tolerate another antitumor necrosis factor (TNF) agent without recurrent DILE. We reviewed the case records of patients with infliximab-induced DILE diagnosed at our institute and noted details of their clinical and immunological profile at presentation. In addition, case notes of patients who were treated with a second anti-TNF agent were examined for evidence of recurrent DILE. Thirteen patients with infliximab-induced DILE were identified with a female-to-male ratio of 11:2. Symmetric large joint arthralgias and high titers of antinuclear and antidouble-stranded DNA antibody were noted in all patients. Eight patients were retreated with a second anti-TNF agent (six certolizumab pegol and two adalimumab) of whom two patients (one adalimumab and certolizumab pegol each) developed recurrent DILE following 3 months of therapy with a second anti-TNF agent. One patient discontinued therapy after 2 months despite no recurrence of DILE, due to fear of side effects. Five patients remain well with no recurrence of DILE after a median o...Continue Reading

References

Nov 25, 1992·JAMA : the Journal of the American Medical Association·J A Anderson
Nov 10, 1994·The New England Journal of Medicine·J C Roujeau, R S Stern
Jun 6, 2002·Lancet·Stephen B HanauerUNKNOWN ACCENT I Study Group
Jun 24, 2003·The American Journal of Gastroenterology·Adam CheifetzScott Plevy
Oct 12, 2004·Inflammatory Bowel Diseases·Adrienne YoudimMaria T Abreu
May 19, 2005·Arthritis Research & Therapy·Michel De BandtUNKNOWN Club Rhumatismes et Inflammation
Jul 20, 2007·The New England Journal of Medicine·William J SandbornUNKNOWN PRECISE 1 Study Investigators
Jul 20, 2007·The New England Journal of Medicine·Stefan SchreiberUNKNOWN PRECISE 2 Study Investigators
Nov 6, 2007·Seminars in Arthritis and Rheumatism·Michelle F CostaBernard Zimmermann
Dec 25, 2007·Pharmacology & Therapeutics·Daniel TraceyPaul P Tak
Sep 18, 2008·Archives of Dermatological Research·Camilla Dalle VedoveGiampiero Girolomoni
Nov 26, 2008·Best Practice & Research. Clinical Rheumatology·Manuel Ramos-CasalsMunther A Khamashta

❮ Previous
Next ❯

Citations

Dec 25, 2012·Rheumatology International·Özgür AkgülSalih Özgöçmen
Aug 12, 2014·Gastroenterology Clinics of North America·Joseph D Feuerstein, Adam S Cheifetz
Apr 17, 2012·Journal of Crohn's & Colitis·Konstantinos H KatsanosEpameinondas V Tsianos
Nov 13, 2015·Expert Opinion on Drug Safety·Itishree Trivedi, Stephen B Hanauer
Oct 2, 2015·Seminars in Immunopathology·C Schlapbach, A A Navarini
Sep 4, 2012·Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG·Camilla Dalle VedoveGiampiero Girolomoni
Dec 3, 2014·Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology·Anna Yuan, Sook-Bin Woo
Apr 10, 2013·Orvosi hetilap·Nóra GyöngyösiNorbert Wikonkál
Jan 13, 2015·Inflammatory Bowel Diseases·Joseph D FeuersteinAdam S Cheifetz
Mar 12, 2013·Inflammatory Bowel Diseases·Joana TorresJean-Frédéric Colombel
Nov 2, 2012·Current Opinion in Rheumatology·Roberto Perez-AlvarezUNKNOWN BIOGEAS study group
Nov 14, 2019·Arthritis Research & Therapy·Michel De Bandt
Oct 25, 2017·Clinical Rheumatology·Ora ShovmanYehuda Shoenfeld

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.